1985

Olavi Kajander, MD, PhD observes nanoscale particles in cultures, forming a community, as contaminants in mammalian cell cultures. He surmises that they may be alive. Other Labs fail to grow them due to the particles’ nanoscopic size and slow growth.

1986

Kajander observes that some of the particles he found earlier appear to have a hard surface.

1987

Kajander discovers the unique calcific particles in human blood.

1988

Kajander takes first electron microscope pictures of nanobacteria and develops polyclonal antibodies to detect them.

1990

Kajander files for patent coverage for nanobacteria, plus culturing and antibody methods.

1991

Kajander develops new monoclonal antibodies to detect nanobacteria.

1992

Kajander is awarded a patent covering nanobacteria and nanobacterial detection methods.

1992

Kajander discovers that nanobacteria make mineralized "igloo-like" structures, explaining the hard surfaces observed earlier.

1992

Kajander et al. publish one of the first abstracts on a unique undescribed blood nanobacteria: Nanobacterium sanguineum.

1992

Kajander optimizes the culturing process by developing a unique medium that makes nanobacteria grow quickly and produces their colonies on solid media.

1993

Kajander and his Finnish company Nanobac OY optimize methods for detecting nanobacteria antigen as a prototype for the commercial methods used today.

1996

Family Practitioner, Gary Mezo invents & develops NanobacTX, a pharmaceutical compound designed to reverse coronary artery disease and begins initial observational clinical trials. Mezo then starts NanobacLabs Pharmaceuticals, the precursor to his Nanobac Pharmaceuticals, Inc. that becomes a US publicly traded company. Mezo later purchases Kajander's Finnish Company Nanobac OY and their patents from the Finnish Government. Mezo hires the discoverer of Nanobacteria, E. Olavi Kajander, MD, PhD and uses Nanobac OY as a Company research center. 

1997

Kajander et al. announce discovery of nanobacteria contamination in antibody products & vacines made w fetal bovine serum.

1997

Kajander, et al announce discovery that nanobacteria replicate in rabbits, fulfilling another part of Koch’s postulates.

1998

Kajander announces discoveries & applies for a patent which was later allowed by European and American agencies.

1998

Kajander announces discovery of nanobacteria in kidney stones. The story is covered by journals and worldwide news.

1998

Kajander announces discovery of nanobacteria in periodontal disease plaque and dental pulp stones.

1999 

László Puskás, PhD (University of Szeged) collaborates with Kajander and Ciftcioglu to detect nanobacteria in arteriosclerotic heart plaques and submits his research findings to prominent scientific journals but cannot get his new findings published.

1999

Nanobac Oy, a Finnish start-up company, begins using diagnostic tests for diagnosing nanobacteria in research patients with heart and kidney disease.

1999

Nanobac Oy, a Finnish start-up company, begins using diagnostic tests for diagnosing nanobacteria in research patients with heart and kidney disease.

1999-2000 

2000

Garcia-Cuerpo et al. fulfill Koch's Postulates for proving nanobacteria as a novel infectious disease-causing agent.

2000

Collaborators @ University of Illinois' Hjelle & Miller announce discovery of nanobacteria in Polycystic Kidney Disease (PKD).

2001

Kajander announces detection of live nanobacteria found as contaminants in sterilized viral vaccines as reported by Vaccines Today and New Scientist.

2001

First Worldwide Nanobacteria Symposium held at University of Kuopio, Finland brings Mezo, Kajander & many other nanobacteria research collaborators together for the first time.

2002

First IRB-monitored Cardiology Clinical Trial on Mezo's NanobacTX begin to show the first formal independent results that severe heart disease patients have sustained substantial reductions in heart disease measurements, symptoms and markers after treatment with NanobacTX.....the first substance ever shown to reduce coronary artery plaque, effectively reversing heart disease. No other substance has ever reversed coronary artery disease plaque.

2002

Rasmussen, et al duplicates Dr. Laszlo Puskas' research work, finding nanobacteria in atherosclerotic plaque.

2002

Kajander announces discovery of contamination of immune gamma globulin products with nanobacteria.

2003

Kerner et al. announce discovery of nanobacteria in polluted river water.

2003

Dr. Maniscalco completes the first clinical trial of NanobacTX and announces significant reductions in coronary artery calcium scores and other markers of heart disease, showing the first formal structural and functional reversal of Coronary Artery Heart Disease. Proving that Mezo's NanobacTX is safe & effective in reversing heart disease.

2003

Dr. Maniscalco completes Mezo's first clinical trial of NanobacTX and announces significant reductions in coronary artery calcium scores and other markers of heart disease, showing the first structural and functional reversal of Coronary Artery Heart Disease.

2003

Gary Mezo, Olavi Kajander & Benedict Maniscalco publish their Unified Theory of Atherogenesis based on nanobacterial infection, calcification, inflammation & swelling and the reversal of heart disease with NanobacTX.

2003

Roland Sedivy and Walter B. Battistutti announce discovery of nanobacteria in calcified adenocarcinomas in ovarian cancer.

2004

Madhu Khullar, S. K. Sharma, S. K. Singh, Pratibha Bajwa, Farooq A. Sheikh, Vandana Relan and Meera Sharma announce that they have isolated nanobacteria from human kidney stones.

2004

The Sino-Finland Nanobacteria Co-Operation Center, an international institute devoted to the study of nanobacteria is started by the University of Kuopio in Finland and the Second Affiliated Hospital Central South University, Changsha, China., to be directed by Kajander.

2004

Jelic, Malas, Groves et al announce independent discovery of nanobacteria in the heart valve of end-stage diabetes patient.

2004

Mayo Clinic's Cockerill & Lieske announce that they have found RNA-synthesizing nanobacteria in cardiovascular disease.

2004

Stephen Epstein, MD, PhD (NIH Head of Cardiovascular Research & Chief of CV Research at Washington Hospital Medical Center) and Jianhui Zhu, PhD present at the American Heart Assn. Annual Meeting their discovery of a correlation between high levels of coronary artery calcification and
nanobacteria antigen, They also established that Nanobacterial antigen & antibodies are a higher heart disease risk-factor than is homocysteine or cholesterol. Epstein's studies were done using Mezo's rapid Nanobacteria test that can also serve as a tool for establishing & predicting heart disease risk.

2005

NASA's Nanobacteria Research Center announces that Nanobacteria grow faster in microgravity which may explaining why astronauts rapidly develop kidney stones & prostate stones during space flights.

2005

Wen, Y., Kajander, et al annouce that they have detected nanobacteria in serum, bile, and gallbladder mucosa of patients with cholecystolithiasis (gallstones).

2005

Prostate researcher, Cleveland Clinic's Daniel Shoskes, MD publishes his Urobac study in The Journal of Urology showing our Urobac is effective in reversing chronic prostatitis (CP), chronic pelvic pain syndrome (CPPS) and prostate stones where all previous forms of medical therapy previously failed.

2005

Tsurumoto, Matsumoto, et al publish their detection of nanobacteria in human arthritic synovial joint fluids.

Multiple additional studies published by Mayo Clinic, Cleveland Clinic, NASA, Baylor, UCSF and scores more....

2006-2011

Multiple researchers independently publish confirmatory research, further validating original findings.

Mezo develops additional Nanobiotics: Dermabac & RegenurEYES.